Slide 1: A Pioneer & Leader in Placental Biologics: Q4:22 & Full Year 2022 Results
Exhibit 99.2 A PIONEER & LEADER IN PLACENTAL BIOLOGICS Q4:22 & Full Year 2022 Results Conference Call February 28, 2023
Slide 2: Disclaimer & Cautionary Statements
Disclaimer & Cautionary Statements Some of the information and statements contained in this presentation and certain oral statements made from time to time by representatives of MIMEDX constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 th
Slide 3: Disclaimer & Cautionary Statements
Disclaimer & Cautionary Statements Additional forward-looking statements may be identified by words such as believe, expect, may, plan, potential, will, preliminary, and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to ris
Slide 4: Joe Capper, Chief Executive Officer
Joe Capper Chief Executive Officer 4
Slide 5: Strong Foundation & A Pioneer & Leader in Placental Biologics
Strong Foundation & A Pioneer & Leader in Placental Biologics Exciting Potential for Value Creation Large Potential Opportunity with Knee Osteoarthritis (“KOA”) Program Strong end to 2022 with highest reported net sales since Q4:19 Q4 5
Slide 6: Why MIMEDX?
Why MIMEDX? Leading and growing product portfolio built on best-in-class Products technology Dedicated & talented employee base making a difference in the lives of People the patients we serve A strong profile today with significant opportunity to further Financial Profile improve on the way to sust
Slide 7: Where We Are Headed
Where We Are Headed Build on our Leadership Position in Wound & Surgical 1 Expand into Adjacent Markets, Including KOA 2 Demonstrate Expense Control & Continuous Process Improvement 3 Focusing the Business on 3 Growth Objectives for Long-Term Success 7
Slide 8: Pete Carlson, Chief Financial Officer
Pete Carlson Chief Financial Officer 8
Slide 9: Net Sales, Gross Profit & Gross Margin
Net Sales, Gross Profit & Gross Margin Net Sales Gross Profit & Gross Margin • Q4:22 represents the $74.4 highest quarterly net sales $67.4 since Q4:19 $60.0 $56.7 • Growth in both Wound & Surgical with strong contributions from 84% 81% recently launched products • Q4:22 gross margin negatively impa
Slide 10: Operating Expenses, Net Income/Loss & Adjusted EBITDA
Operating Expenses, Net Income/Loss & Adjusted EBITDA Q4:21 Q4:22 $37.7 $36.2 • Significant actions taken $15.1 $12.3 to improve Company’s $3.6 $2.8 $1.8 $1.8 $1.8 $0.0 cost base W&S RM Corporate W&S RM SG&A R&D • Focused on Q4:21 demonstrating expense Q4:22 control and improving $7.3 profitability
Slide 11: Full Year 2022 Results
Full Year 2022 Results Net Sales $267.8 million Adjusted EBITDA $3.9 million +3.6% growth vs. 2021 as-reported vs. $18.7 million in 2021 +10.5% growth from continuing product portfolio Gross Margin 82.0% Wound & Surgical $66.7 million Negatively impacted by lower 25.2% of segment sales production vo
Slide 12: Year End 2022 Cash Position
Year End 2022 Cash Position $87.1 $75.7 • Balance sheet and $73.2 $72.5 disciplined cash $66.0 management continues • Q4:22 includes initial payment to Turn Therapeutics for access to antimicrobial IP • Do not currently anticipate need to raise additional capital to fund operations and R&D efforts,
Slide 13: Looking Forward
Looking Forward Goal to deliver low double digit percentage annual net sales growth Revenue Growth Goal 2023 expected to be characterized by ongoing challenges in private physician office setting Focused on profitability targets, including: Expense Discipline • Wound & Surgical segment contribution
Slide 14: Joe Capper, Chief Executive Officer
Joe Capper Chief Executive Officer 14
Slide 15: Clear Momentum to End 2022 and Start 2023
Clear Momentum to End 2022 and Start 2023 Numerous changes to Adoption of new Strong quarterly drive increased Great finish to 2022… products, commercial revenue growth of 10% efficiency and expense focus & execution rationalization Launched EPIFIX® in …and a strong start to Added experienced Japan
Slide 16: Changes to CMS Physician Office Reimbursement
Changes to CMS Physician MIMEDX is Uniquely Positioned to Benefit from Office Reimbursement Potential Changes in Physician Office Setting are Needed Skin Substitute Products – Medicare Allowed Charges $1,000,000,000 • Skin Substitute Products Previously NOT on ASP List have Led to Explosion of Medic
Slide 17: Conclusion
Conclusion Strong business Dedicated team Growing revenue Deep pipeline with products committed to our base and with numerous that make a Mission improving opportunities for positive profitability continued growth difference in the lives of patients a pioneer & leader in placental biologics 17
Slide 18: MIMEDX
MIMEDX cy